공시 • Jun 23
Glorious Success Limited signed a letter of intent to acquire Biocure Technology Inc. (CNSX:CURE.X) in a reverse merger transaction. Glorious Success Limited signed a letter of intent to acquire Biocure Technology Inc. (CNSX:CURE.X) in a reverse merger transaction on June 22, 2026. Upon the successful completion of the proposed Transaction, it is anticipated that Biocure Technology Inc. will carry on the business of GSL. Pursuant to the Transaction, CURE will consolidate its existing share capital on the basis of a ratio determined by the price of GSL securities in the Private Placement divided by a deemed value of CAD 0.134 (the “Consolidation”), currently expected to result in a consolidation ratio equal to approximately 16.42 old shares for one new common share (the “Resulting Issuer Shares”). As consideration for the outstanding shares of GSL, including GSL Shares issuable in the Private Placement and GSL Debt Settlement, CURE will issue Resulting Issuer Shares on the basis of exchange ratio. Based on the expected terms of the Private Placement and GSL Debt Settlement, it is expected that an aggregate of 11,363,636 Resulting Issuer Shares will be issued to existing holders and GSL Shares prior to completion of the Private Placement and GSL Debt Settlement. Following completion of the Consolidation, Transaction, Private Placement and debt settlements, the Resulting Issuer is expected to have 15,980,788 Resulting Issuer Shares outstanding of which existing shareholders of CURE will represent 8.1% of the outstanding Resulting Issuer Shares. Pursuant to the letter agreement, it is a condition of the Transaction that GSL complete a private placement for aggregate gross proceeds of at least CAD 3.09 million. The Resulting Issuer intends to use the proceeds of the private placement to fund the Transaction. Upon completion of the Transaction, CURE intends to change its name to a new name to be determined by the parties and the parties expect that the CSE will assign a new trading symbol for the Resulting Issuer.
Upon completion of the Transaction, the board of the Resulting Issuer shall be reconstituted to consist of a number of directors, the majority of which will be nominated by GSL, provided that Collin Kim will remain on the board of directors of the Resulting Issuer and Konstantin Lichtenwald will continue to serve as Chief Financial Officer. GSL is entitled to select a Chief Executive Officer for the Resulting Issuer.
The Transaction is subject to a number of terms and conditions, including, but not limited to, the completion of satisfactory due diligence, the parties entering into the Definitive Agreement with respect to the Transaction on or before September 15, 2026, the completion of the Consolidation, the completion of the Private Placement, the completion of debt settlements by both GSL and CURE, the approval of the shareholders of CURE and GSL (if required), and the approval of the CSE and other applicable regulatory authorities. Approval for the Transaction, including the Consolidation, will be sought from the CURE’s shareholders at a meeting to be held on a date to be determined. Board Change • May 20
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Collin Kim was the last independent director to join the board, commencing their role in 2015. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. 공시 • May 28
Biocure Technology Inc., Annual General Meeting, Jul 30, 2025 Biocure Technology Inc., Annual General Meeting, Jul 30, 2025. Location: british columbia, vancouver Canada 공시 • Apr 22
Biocure Technology Inc. announced that it expects to receive CAD 0.15 million in funding Biocure Technology Inc. announced a non-brokered private placement financing of up to 7,500,000 units at CAD 0.02 per Unit of the Company for aggregate proceeds of up to CAD 150,000 on April 21, 2025. Each Unit will consist of one 1 common share in the capital of the Company and one
transferrable common share purchase warrant. Each Warrant entitles the holder thereof to purchase one Share at a price of CAD 0.05 for a period of five (5) years from the date of issuance. The issuance of securities in connection with this Offering will be subject to Canadian Securities Exchange (“CSE”) approval and the securities will be subject to a statutory hold period of four months plus one day from the date of issuance in accordance with applicable Canadian securities laws. 공시 • Dec 20
Biocure Technology Inc. announced that it expects to receive CAD 0.2 million in funding Biocure Technology Inc. announced a non-brokered financing to raise 10,000,000 common shares at an issue price of CAD 0.02 per share for the gross proceeds of CAD 200,000 on December 19, 2024. No finders' fees are expected to be paid on any portion of the placement. No new insiders or control persons are expected to be created as a result of the placement. Existing insiders of the company are expected to participate in the placement. Board Change • Oct 29
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Collin Kim was the last independent director to join the board, commencing their role in 2015. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. 